Free Trial

Centessa Pharmaceuticals (CNTA) Stock Price, News & Analysis

Centessa Pharmaceuticals logo
$14.22 +0.19 (+1.35%)
As of 10:53 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Centessa Pharmaceuticals Stock (NASDAQ:CNTA)

Key Stats

Today's Range
$13.85
$14.35
50-Day Range
$11.86
$14.34
52-Week Range
$9.00
$19.09
Volume
74,761 shs
Average Volume
748,643 shs
Market Capitalization
$1.90 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$27.89
Consensus Rating
Buy

Company Overview

Centessa Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
52nd Percentile Overall Score

CNTA MarketRank™: 

Centessa Pharmaceuticals scored higher than 52% of companies evaluated by MarketBeat, and ranked 352nd out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Centessa Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Centessa Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

  • Read more about Centessa Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Centessa Pharmaceuticals are expected to grow in the coming year, from ($1.60) to ($1.50) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Centessa Pharmaceuticals is -7.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Centessa Pharmaceuticals is -7.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Centessa Pharmaceuticals has a P/B Ratio of 4.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Centessa Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    5.27% of the float of Centessa Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Centessa Pharmaceuticals has a short interest ratio ("days to cover") of 4.6.
  • Change versus previous month

    Short interest in Centessa Pharmaceuticals has recently decreased by 15.02%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Centessa Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Centessa Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.27% of the float of Centessa Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Centessa Pharmaceuticals has a short interest ratio ("days to cover") of 4.6.
  • Change versus previous month

    Short interest in Centessa Pharmaceuticals has recently decreased by 15.02%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Centessa Pharmaceuticals this week, compared to 5 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Centessa Pharmaceuticals insiders have bought 138.22% more of their company's stock than they have sold. Specifically, they have bought $5,866,687.00 in company stock and sold $2,462,692.00 in company stock.

  • Percentage Held by Insiders

    Only 7.09% of the stock of Centessa Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    82.01% of the stock of Centessa Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Centessa Pharmaceuticals' insider trading history.
Receive CNTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Centessa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CNTA Stock News Headlines

I was wrong about Trump
I made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.
CNTA Centessa Pharmaceuticals plc - Seeking Alpha
Centessa announces clearance of IND for ORX142
See More Headlines

CNTA Stock Analysis - Frequently Asked Questions

Centessa Pharmaceuticals' stock was trading at $16.75 at the beginning of the year. Since then, CNTA stock has decreased by 16.2% and is now trading at $14.03.

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) issued its earnings results on Monday, May, 12th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.15.

Centessa Pharmaceuticals (CNTA) raised $285 million in an initial public offering (IPO) on Friday, May 28th 2021. The company issued 15,000,000 shares at $18.00-$20.00 per share. Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Jefferies and Evercore ISI were co-managers.

Shares of CNTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Centessa Pharmaceuticals investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), TotalEnergies (TTE), The RMR Group (RMR) and Southern First Bancshares (SFST).

Company Calendar

Last Earnings
5/12/2025
Today
7/10/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CNTA
CIK
1847903
Fax
N/A
Employees
200
Year Founded
N/A

Price Target and Rating

High Price Target
$38.00
Low Price Target
$6.00
Potential Upside/Downside
+96.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
10 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$235.76 million
Pretax Margin
-1,467.24%

Debt

Sales & Book Value

Annual Sales
$6.85 million
Price / Cash Flow
N/A
Book Value
$3.05 per share
Price / Book
4.66

Miscellaneous

Free Float
124,086,000
Market Cap
$1.90 billion
Optionable
Optionable
Beta
1.45
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:CNTA) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners